ArticleThe primary care companion for CNS disorders2013
A review of therapeutic uses of mirtazapine in psychiatric and medical conditions.
Article in The primary care companion for CNS disorders, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder.Journal of addiction medicineGuideline
- A Preliminary Study of Different Treatment Strategies for Anxious Depression.Neuropsychiatric disease and treatment · 2022Trial
- Mirtazapine reduces susceptibility to hypocapnic central sleep apnea in males with sleep-disordered breathing: a pilot study.Journal of applied physiology (Bethesda, Md. : 1985) · 2021Trial
- Effect of mirtazapine on pruritus in patients on hemodialysis: a cross-over pilot study.International urology and nephrology · 2020Trial
- Naltrexone/Bupropion/Mirtazapine Triple Therapy for Treatment-Resistant Methamphetamine Use Disorder: A Case Series.Cureus · 2026Article
- Formulation and characterization of Mirtazapine loaded mucoadhesive cubosomal in-situ gel for intranasal delivery.Therapeutic delivery · 2025Article
- Using Natural Language Processing to develop risk-tier specific suicide prediction models for Veterans Affairs patients.Journal of psychiatric research · 2024Article
- A peculiar presentation of mirtazapine-induced melasma: A very rare case report.Indian journal of psychiatry · 2024Article
- Mirtazapine Therapy for a Patient With Weight Loss and Gastroparesis Associated With Limited Systemic Sclerosis.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2024Article
- Mirtazapine for gastrointestinal and neuropsychological symptoms in older adults with irritable bowel syndrome.Therapeutic advances in gastroenterology · 2024Review
- Changes in prescribing of psychotropic vs some physical health medication in primary care through the COVID-19 pandemic in England: a national-level survey.Journal of pharmaceutical policy and practice · 2023Article
- Review
- Combination of antidepressants and antipsychotics as a novel treatment option for psychosis in Alzheimer's disease.CPT: pharmacometrics & systems pharmacology · 2023Article
- Cerebral chemoarchitecture shares organizational traits with brain structure and function.eLife · 2023Article
- Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review.International journal of molecular sciences · 2022Review
- Article
- Antidepressants in Alzheimer's Disease: A Focus on the Role of Mirtazapine.Pharmaceuticals (Basel, Switzerland) · 2021Review
- A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome.BioPsychoSocial medicine · 2021Article
- Comparative efficacy of placebos in short-term antidepressant trials for major depression: a secondary meta-analysis of placebo-controlled trials.BMC psychiatry · 2020Article
- Orthorexia nervosa and comorbid depression successfully treated with mirtazapine: a case report.Eating and weight disorders : EWD · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo review the literature examining the use of mirtazapine with an emphasis on its therapeutic benefits for psychiatric patients with comorbid medical conditions. DATA SOURCES: MEDLINE, PsycINFO, Global Health, and AGRICOLA were searched using the terms mirtazapine OR Remeron. Limits were English language, human, year 1980-2012, treatment and prevention, and therapy. STUDY SELECTION: Two hundred ninety-three articles were identified. DATA EXTRACTION: Identified articles were reviewed with a focus on indications and therapeutic benefits in patients with medical comorbidities.
resultsMirtazapine is an effective antidepressant with unique mechanisms of action. It is characterized by a relatively rapid onset of action, high response and remission rates, a favorable side-effect profile, and several unique therapeutic benefits over other antidepressants. Mirtazapine has also shown promise in treating some medical disorders, including neurologic conditions, and ameliorating some of the associated debilitating symptoms of weight loss, insomnia, and postoperative nausea and vomiting.
conclusionsMirtazapine offers clinicians multiple therapeutic advantages especially when treating patients with comorbid medical illness.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.